Segui
Miriam Martini
Miriam Martini
Email verificata su unito.it - Home page
Titolo
Citata da
Citata da
Anno
Effects of KRAS, BRAF, NRAS, and PIK3CA mutations on the efficacy of cetuximab plus chemotherapy in chemotherapy-refractory metastatic colorectal cancer: a retrospective …
W De Roock, B Claes, D Bernasconi, J De Schutter, B Biesmans, ...
The lancet oncology 11 (8), 753-762, 2010
25782010
Wild-Type BRAF Is Required for Response to Panitumumab or Cetuximab in Metastatic Colorectal Cancer
F Di Nicolantonio, M Martini, F Molinari, A Sartore-Bianchi, S Arena, ...
Journal of clinical oncology 26 (35), 5705-5712, 2008
21602008
PI3K/AKT signaling pathway and cancer: an updated review
M Martini, MC De Santis, L Braccini, F Gulluni, E Hirsch
Annals of medicine 46 (6), 372-383, 2014
11522014
PIK3CA mutations in colorectal cancer are associated with clinical resistance to EGFR-targeted monoclonal antibodies
A Sartore-Bianchi, M Martini, F Molinari, S Veronese, M Nichelatti, ...
Cancer research 69 (5), 1851-1857, 2009
9272009
Multi-determinants analysis of molecular alterations for predicting clinical benefit to EGFR-targeted monoclonal antibodies in colorectal cancer
A Sartore-Bianchi, F Di Nicolantonio, M Nichelatti, F Molinari, S De Dosso, ...
PloS one 4 (10), e7287, 2009
3202009
Measurement of PIP3 levels reveals an unexpected role for p110β in early adaptive responses to p110α-specific inhibitors in luminal breast cancer
C Costa, H Ebi, M Martini, SA Beausoleil, AC Faber, CT Jakubik, A Huang, ...
Cancer cell 27 (1), 97-108, 2015
2052015
PI3K class II α controls spatially restricted endosomal PtdIns3P and Rab11 activation to promote primary cilium function
I Franco, F Gulluni, CC Campa, C Costa, JP Margaria, E Ciraolo, ...
Developmental cell 28 (6), 647-658, 2014
2052014
Phosphoinositide 3-kinase gamma inhibition protects from anthracycline cardiotoxicity and reduces tumor growth
M Li, V Sala, MC De Santis, J Cimino, P Cappello, N Pianca, A Di Bona, ...
Circulation 138 (7), 696-711, 2018
1652018
Targeted therapies: how personal should we go?
M Martini, L Vecchione, S Siena, S Tejpar, A Bardelli
Nature reviews Clinical oncology 9 (2), 87-97, 2012
1422012
Targeting PI3K in cancer: any good news?
M Martini, E Ciraolo, F Gulluni, E Hirsch
Frontiers in oncology 3, 108, 2013
1322013
Class II PI3K functions in cell biology and disease
F Gulluni, MC De Santis, JP Margaria, M Martini, E Hirsch
Trends in cell biology 29 (4), 339-359, 2019
1222019
Replacement of normal with mutant alleles in the genome of normal human cells unveils mutation-specific drug responses
F Di Nicolantonio, S Arena, M Gallicchio, D Zecchin, M Martini, SE Flonta, ...
Proceedings of the National Academy of Sciences 105 (52), 20864-20869, 2008
1142008
Targeting PI3K signaling in cancer: Challenges and advances
MC De Santis, F Gulluni, CC Campa, M Martini, E Hirsch
Biochimica et Biophysica Acta (BBA)-Reviews on Cancer 1871 (2), 361-366, 2019
822019
PI3K in cancer–stroma interactions: bad in seed and ugly in soil
E Hirsch, E Ciraolo, I Franco, A Ghigo, M Martini
Oncogene 33 (24), 3083-3090, 2014
782014
Mitotic spindle assembly and genomic stability in breast cancer require PI3K-C2α scaffolding function
F Gulluni, M Martini, MC De Santis, CC Campa, A Ghigo, JP Margaria, ...
Cancer Cell 32 (4), 444-459. e7, 2017
772017
PI (3, 4) P2 signaling in cancer and metabolism
L Gozzelino, MC De Santis, F Gulluni, E Hirsch, M Martini
Frontiers in oncology 10, 360, 2020
652020
Signaling pathways regulating redox balance in cancer metabolism
MC De Santis, PE Porporato, M Martini, A Morandi
Frontiers in oncology 8, 126, 2018
652018
Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia
A Bottos, M Martini, F Di Nicolantonio, V Comunanza, F Maione, ...
Proceedings of the National Academy of Sciences 109 (6), E353-E359, 2012
592012
PI3K keeps the balance between metabolism and cancer
L Braccini, E Ciraolo, M Martini, T Pirali, G Germena, K Rolfo, E Hirsch
Advances in biological regulation 52 (3), 389-405, 2012
542012
Prospects of targeting PI3K/AKT/mTOR pathway in pancreatic cancer
M Mortazavi, F Moosavi, M Martini, E Giovannetti, O Firuzi
Critical reviews in oncology/hematology 176, 103749, 2022
532022
Il sistema al momento non può eseguire l'operazione. Riprova più tardi.
Articoli 1–20